Details

---

Manufacturer
Cilag AG(SWITZERLAND)

Registraction Number
MAL19096009AZ

Content:

• Active Ingredient: Guselkumab (100mg/mL)
• Form: Solution for subcutaneous injection

Indications:
TREMFYA is indicated for the treatment of:

• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• Active psoriatic arthritis in adults
• Moderately to severely active ulcerative colitis in adults

 Instructions:

• Dosage for Plaque Psoriasis: 100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
• Dosage for Psoriatic Arthritis: 100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. TREMFYA can be used alone or in combination with a conventional DMARD (e.g., methotrexate).
• Dosage for Ulcerative Colitis: Induction: 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. Maintenance: 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.